CJC-1295 (No DAC) vs Dihexa: Mechanism, Half-Life & Research Use

Direct Comparison: CJC-1295 (No DAC) vs Dihexa Overview

CJC-1295 (No DAC) and Dihexa differ primarily in their primary receptor targets, biological mechanisms, and physiological research applications. CJC-1295 (No DAC) is a 29-amino-acid tetrasubstituted peptide analog of GHRH that selectively binds to pituitary GHRH receptors, stimulating pulsatile growth hormone (GH) secretion and raising downstream insulin-like growth factor 1 (IGF-1) levels. In contrast, Dihexa is a hexapeptide derivative of angiotensin IV engineered to bind HGF with high affinity, potentiating c-Met receptor dimerization to promote dendritic spinogenesis and neural plasticity in vitro and in vivo.

Investigators selecting between these compounds must consider their contrasting pharmacokinetics, solubility, and signaling cascades. While CJC-1295 (No DAC) exhibits a short plasma half-life of roughly 30 minutes in rodent models, making it ideal for studying physiological GH pulses, Dihexa demonstrates notable stability and oral/systemic bioavailability in preclinical models, making it suitable for long-term neurobiological assays. Both compounds are strictly intended for laboratory research use, requiring analytical verification to ensure reproducible experimental outcomes.

Key Criteria Comparison Matrix

To assist laboratory personnel in structuring experimental protocols, the core biochemical parameters of both research compounds are outlined below:

1. Receptor Target: CJC-1295 (No DAC) targets the GHRH receptor (GHRHR) on pituitary somatotropes. Dihexa targets Hepatocyte Growth Factor (HGF) and its tyrosine kinase receptor, c-Met. 2. Mechanistic Class: CJC-1295 (No DAC) is a synthetic GHRH secretagogue / somatotrophic peptide. Dihexa is a neurogenic hexapeptide / HGF/c-Met receptor agonist. 3. Preclinical Half-Life: CJC-1295 (No DAC) displays a half-life of ~30 minutes in vivo. Dihexa exhibits high metabolic stability with a prolonged plasma half-life (>12 hours in rodent assays). 4. Aqueous Solubility: CJC-1295 (No DAC) is highly soluble in sterile water or buffered saline. Dihexa exhibits moderate aqueous solubility and frequently requires DMSO or specific solubilization matrices for high-concentration stock solutions. 5. Primary Research Models: CJC-1295 (No DAC) is utilized in rodent models of metabolic rate, endocrine axis, and musculoskeletal tissue repair. Dihexa is primarily investigated in neurodegenerative rodent models, traumatic brain injury assays, and primary neuronal cell cultures. 6. Standard Packaging: Both compounds are available from PX1 Research as lyophilized research-grade reagents, typically supplied in 2mg to 5mg vials.

Researchers evaluating these technical criteria can streamline solvent selection, buffer prep, and concentration curves based on the target pathway required by their study design.

CJC-1295 (No DAC): Receptor Activation and Somatotrophic Kinetics

Synthesized as a modified fragment of native GHRH(1-29), CJC-1295 (No DAC) incorporates D-alanine, glutamine, alanine, and leucine substitutions at positions 2, 8, 15, and 27, respectively. These modifications increase resistance to enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV), thereby extending its biological activity relative to endogenous GHRH without creating the permanent albumin-binding affinity seen in Drug Affinity Complex (DAC) variants.

In preclinical endocrine models, CJC-1295 (No DAC) binds to GHRHR, initiating G-protein-coupled signaling that activates adenylate cyclase and increases intracellular cAMP. This cascade triggers the secretion of growth hormone from anterior pituitary somatotropes. Because it lacks the DAC moiety, CJC-1295 (No DAC) mimics the physiological, pulsatile release of GH rather than inducing continuous, non-pulsatile secretion. Researchers investigating tissue repair, nitrogen retention, collagen synthesis, and cell growth utilize CJC-1295 (No DAC) to evaluate how physiological GH/IGF-1 pulses influence systemic cellular recovery.

Dihexa: HGF/c-Met Cascade and Synaptogenic Mechanisms

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) represents an entirely different class of synthetic oligopeptides. Developed via structure-activity relationship studies of angiotensin IV, Dihexa was engineered to overcome the rapid metabolic degradation typical of short biological peptides. It functions by binding directly to HGF with high affinity (Kd in the low picomolar range), facilitating HGF dimerization and subsequent phosphorylation of the c-Met receptor tyrosine kinase domain.

The c-Met signaling pathway plays a vital role in cellular survival, cell migration, and neuroplasticity. Preclinical neurobiology studies indicate that Dihexa-mediated c-Met activation triggers extracellular signal-regulated kinase (ERK) and AKT signaling pathways. In primary hippocampal neuron cultures and animal models of cognitive impairment, Dihexa administration has been observed to stimulate robust dendritic spine formation (spinogenesis) and synapse assembly, even at low nanomolar concentrations. This profile positions Dihexa as a valuable tool for investigating neurogenesis, cognitive repair, and synaptic connectivity.

Pharmacokinetics, Half-Life, and Solution Stability

Understanding the kinetic profiles of these two reagents is critical for designing appropriate dosing intervals in animal models or incubation periods in cell-based assays. CJC-1295 (No DAC) demonstrates an in vivo biological half-life of approximately 30 minutes in rodent pharmacokinetic assays. This rapid clearance rate requires researchers to implement timed, pulsatile administration schedules if long-term somatotrophic elevation is desired, preventing receptor desensitization.

Conversely, Dihexa possesses remarkable metabolic stability against systemic peptidases. In vivo pharmacokinetic studies report high biological stability, allowing for single daily or intermittent experimental protocols in rodent models. Additionally, Dihexa retains stability across broad pH ranges, though its lipophilic hexanoyl group necessitates careful preparation when establishing aqueous media dilutions. Laboratory protocols requiring accurate volume and concentration calculations should utilize our reconstitution calculator to determine correct liquid handling parameters before mixing stock solutions.

Downstream Signaling: Somatotrophic Axis vs. Neural Plasticity

The physiological outcomes evaluated when testing CJC-1295 (No DAC) versus Dihexa highlight their differing biological targets. CJC-1295 (No DAC) acts globally across tissues expressing IGF-1 receptors. Downstream targets of somatotrophic activation include skeletal muscle satellite cell proliferation, osteoblast activity, dermal fibroblast collagen expression, and hepatic lipid oxidation. Preclinical studies suggest that elevated GH and IGF-1 levels enhance protein synthesis rates in damaged musculoskeletal tissues.

In contrast, Dihexa's downstream pathways center on cellular repair within the central and peripheral nervous systems. Activation of the c-Met receptor by Dihexa leads to actin cytoskeletal remodeling within neuronal growth cones, expanding the density of functional glutamate synapses. While CJC-1295 (No DAC) influences systemic tissue repair via systemic endocrine pathways, Dihexa operates locally and centrally on structural neural remodeling. Researchers can explore additional molecular literature on these pathways in our dedicated research library.

Comparative Class Analysis: GHRH Analogs and Neurogenic Peptides

Placing CJC-1295 (No DAC) and Dihexa within their broader peptide classes helps contextualize their scientific utility. Within the GHRH secretagogue class, CJC-1295 (No DAC) is frequently evaluated alongside peptides like Sermorelin, an earlier 29-amino-acid GHRH fragment, and ghrelin receptor agonists such as Ipamorelin. Combined research models testing CJC-1295 (No DAC) with selective GH secretagogues aim to measure potential synergistic GH release via simultaneous GHRHR and GHSR activation.

Dihexa, meanwhile, belongs to an emerging category of neurogenic and regenerative oligopeptides that includes compounds like BPC-157 and selective neurotrophic fragments. Unlike systemic tissue repair compounds that operate through vascular endothelial growth factor (VEGF) or growth hormone secretion, Dihexa remains uniquely selective for the HGF/c-Met axis. Understanding these class distinctions allows laboratories to select peptides that match their exact receptor requirements, whether targeting systemic endocrine axes or specialized central nervous system signaling pathways.

Study Design Selection: Matching the Compound to the Model

Selecting the ideal reagent depends strictly on the research objectives outlined in the experimental design. If the study protocol aims to evaluate:

- Endocrine somatotrophic signaling, serum IGF-1 kinetics, muscle protein synthesis, or cellular regeneration following physical injury, **CJC-1295 (No DAC)** is the appropriate primary reagent. - Synaptic density changes, dendritic spine arborization, memory acquisition models, or neurodegenerative damage repair, **Dihexa** is the targeted candidate. - Combined metabolic and neuro-trophic interactions, investigators must establish non-interfering assay conditions, accounting for the different solvent requirements and receptor targets of both compounds.

For laboratories scaling up high-throughput screens or multi-animal cohort studies, registering for a wholesale account provides access to bulk research quantities, lot-matched consistency, and dedicated technical documentation.

Analytical Quality Standards and Reconstitution Guidelines

Maintaining rigorous experimental reproducibility requires high-purity research compounds free from bacterial endotoxins, TFA salts, and truncated sequence impurities. PX1 Research synthesizes all peptides in GMP-compliant, USA-based facilities. Every batch undergoes rigorous HPLC and mass spectrometry analysis to guarantee purity levels exceeding 99%.

Laboratory technicians should consult the lot-specific certificate of analysis (COA) prior to experiment initiation. To reconstitute CJC-1295 (No DAC), add sterile bacteriostatic water directly to the lyophilized cake, allowing the peptide to dissolve gently without aggressive vortexing. For Dihexa, stock solutions may require an initial dimethyl sulfoxide (DMSO) solubilization step prior to dilution into aqueous culture media or physiological saline buffers to prevent precipitation. Aliquoted stock solutions should be stored at -80°C to preserve peptide integrity over extended research timelines.